Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2019-2024), with a CAGR of 14.5%, mainly as a result of new drug launches.
Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe.
Europe’s expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal.
In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
The European region suffers from a high burden of diabetes, and its adverse health and economic consequences.
The disease is viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in the United Kingdom.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends
Ever Increasing Burden of Diabetes in the European Region
As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
Germany to Dominate the Europe GLP-1 Market
Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all the regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly over the forecast period, because of Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
5.2.1 Europe
5.2.1.1 Germany (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Spain (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Italy (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
5.2.1.4 France (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 UK (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Russia (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Glucagon like Peptide 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.
Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.
In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly’s Trulicity will dominate the market during the forecast period.
Scope of the Report
The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.
Key Market Trends –
Constant Global Trend of High Diabetes Prevalence
The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
North America to Dominate the Market in Terms of Revenue
North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding a presence in all regions.
Currently, no generic versions of the GLP-1s are available in the market, since the drugs are patent protected. However, Teva confirmed generic Victoza and announced that it had filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market the generic version of Novo Nordisk’s Victoza® (liraglutide) injection, in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2 Europe
5.2.2.1 Germany (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.2 Spain (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.4 France (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3 Asia-Pacific
5.2.3.1 Japan (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.2 China (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.3 Australia (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.4 India (Value and Volume 2012-2024)
5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.5 South Korea (Value and Volume 2012-2024)
5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.6 Malaysia (Value and Volume 2012-2024)
5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.7 Indonesia (Value and Volume 2012-2024)
5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.8 Thailand (Value and Volume 2012-2024)
5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.9 Philippines (Value and Volume 2012-2024)
5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4 Latin America
5.2.4.1 Brazil (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.2 Mexico (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5 Middle East & Africa
5.2.5.1 South Africa (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.3 Oman (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.4 Egypt (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.5 Iran (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
North America
US (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Canada (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of North America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Europe
Germany (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Spain (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Italy (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
(Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
France (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
UK (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Russia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
China (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Australia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
India (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Korea (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Malaysia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Indonesia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Thailand (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Philippines (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Latin America
Brazil (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Mexico (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Middle East & Africa
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Middle East & Africa Glucagon-like Peptide – 1 (GLP – 1) Agonists Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 13-06-2019
Market Overview
For the last three decades, the Middle East & African countries have witnessed some critical social and economic transformations, which involve rapid economic growth and urbanization, along with reduced infant mortality and increased life expectancy.
Meanwhile, a few countries in the region have seen a decreased economy, due to political tension, along with other social factors, such as terrorism.
In the Middle East & Africa, approximately 35.5 million people live with diabetes. Middle Eastern countries have a high diabetes prevalence.
For instance, the percentages of type 2 diabetes in a few important countries are as follows: Saudi Arabia 24%, Kuwait 23%, Bahrain 22%, Qatar 20%, and UAE 19%.
It is estimated that only USD 17 billion was spent on diabetes, despite high prevalence in the region. Growth in the number of middle-class households, as well as increasing per capita income in these countries, will result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
Along with this, a few important factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.
The Middle East & Africa region suffers from a high burden of diabetes, and its adverse health and economic consequences. The disease should be viewed as a serious threat, not just from public health, but also from a development perspective. With risk factors, such as increasing obesity, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries in the region. It is one of the most common chronic diseases in Saudi Arabia, followed by Kuwait.
Scope of the Report
The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.
Key Market Trends –
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes, among people of over 18 years, has accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70. WHO projects that diabetes is likely to be the seventh leading cause of death by 2030.
Statistics prove that one in ten individuals in the country has diabetes and a rise in this trend is expected to take the situation to one in three, by 2050 (according to the Center for Disease Control and Prevention).
The growing prevalence of diabetes is the primary driver for the global diabetes care drugs market. Additionally, raising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market.
Saudi Arabia to Lead the GLP-1 Market
The GLP-1 market is expected to witness a high CAGR, of 13.4%, over the forecast period. Saudi Arabia is expected to hold the highest market share in the Middle East & Africa GLP-1 agonist market.
Victoza holds the highest market share in the region and the same trend is seen in Saudi Arabia. Trulicity is expected to have the highest growth during the forecast period (2019-2024)
The Saudi Arabian market is expected to see robust growth during the forecast period (2019-2024), due to the high number of R&D-related investments in the market. Some of these pipeline products are two of Sanofi’s GLP-1s, efpeglenatide and SAR425899, which are expected to launch in 2020 and 2021, respectively.
Competitive Landscape
The global GLP-1 market is consolidated, with four major manufacturers holding their presence in all regions.
The market for GLP-1 agonist drugs includes Victoza, Trulicity, Byetta, Bydureon, and Lyxumia. The market is expected to grow significantly, during the forecast period, due mainly to Trulicity and Ozempic.
Oral Semaglutide, which is in phase 3 of its clinical trials, is expected to launch by 2020. The product has shown better results than Januvia in studies.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Exenatide
5.1.1.1 Byetta (Value and Volume 2012-2024)
5.1.1.2 Bydureon (Value and Volume 2012-2024)
5.1.2 Liraglutide
5.1.2.1 Victoza (Value and Volume 2012-2024)
5.1.3 Lixisenatide
5.1.3.1 Lyxumia (Value and Volume 2012-2024)
5.1.4 Dulaglutide
5.1.4.1 Trulicity (Value and Volume 2012-2024)
5.2 Geography
5.2.1 Middle East & Africa
5.2.1.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.2 Egypt (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.3 Iran (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.4 South Africa (Value and Volume 2012-2024)
5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.5 Oman (Value and Volume 2012-2024)
5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
5.2.1.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 AstraZeneca
7.2 MARKET SHARE ANALYSIS
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Eli Lilly
7.2.4 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Exenatide
Byetta (Value and Volume 2012-2024)
Bydureon (Value and Volume 2012-2024)
Liraglutide
Victoza (Value and Volume 2012-2024)
Lixisenatide
Lyxumia (Value and Volume 2012-2024)
Dulaglutide
Trulicity (Value and Volume 2012-2024)
Geography
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Egypt (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Iran (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
South Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Oman (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Rest of Middle East & Africa (Value and Volume 2012-2024)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
North America Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 75 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 75 pages
- Published: 13-06-2019
Market Overview
The North America sodium-dependent glucose co-transporter 2 (SGLT2) market is expected to witness a tremendous growth during the forecast period (2019 – 2024), with a CAGR of 15.84%, mainly due to Jardiance and Farxiga/Forxiga, which launched globally in 2013 and 2014, respectively.
Jardiance is a once-daily oral medication that is used to control blood glucose levels in people with type 2 diabetes.
Jardiance has the highest growth among all the drugs in the SGLT-2 class of drugs, with a CAGR of about 21.4% during the forecast period (2019-2024). This is mainly because patients prefer this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT-2 class drugs.
Scope of the Report
The SGLT2 class of drugs includes Jardiance, Fraxiga, and Inovokana. The market growth for the drug Invonkana has been decreasing when compared to other SGLT2 class drugs, due to a large number of side effects, such as increasing weight and high cardiovascular risks for the patients. In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Suglat is a SGLT2 drug present only in Japan, with a market value of USD 93.29 million in 2017.
Key Market Trends –
Increasing Diabetes Population
As there is an exponential growth of the diabetes population year on year, especially type-2 diabetes, new innovative drugs are emerging in the market, for ease of access for the patients.
With this increase in diabetes population, the need and demand for diabetes drugs are expected to increase in North America.
The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.
The North American SGLT2 market has a value for USD 4,205.99 million in 2019 and is expected to reach USD, witnessing a growth of 15.56% until the end of the forecast period. The United States accounts for 96.59% of the market, followed by Canada, which contributes around 3% of the SGLT-2 revenue in 2019.
At the brand level, Jardiance holds a significant market share at 43.48% in 2019. Jardiance also has a higher growth rate, at 21.31% which is considerably higher than the other two brands in this segment (Invokana and Farxiga/Forxiga).
The high CAGR can be attributed to the fact that Jardiance was introduced recently and is also used for other indications, such as diabetes-related cardiovascular diseases.
Overall, the SGLT2 market is expected to witness a considerable growth, owing to factors such as the rising diabetes population, constant R&D for the improvement of drug efficiency, and continuous updation of labels, among others.
Competitive Landscape
In June 2018, a new study on Jardiance reflected that the drug helps in reductions of kidney disease and cardiovascular risk.
In July 2017, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, to update the labels of Jardiance.
The labels will now include results from a trial that states that there is a relative risk reduction in hospitalization for heart failure, by 35%, and a relative risk reduction for new-onset or worsening of kidney disease, by 39%.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product (Market Value and Volume, 2012-2024)
5.1.1 Jardiance (Empagliflozin)
5.1.2 Farxiga/Forxiga (Dapagliflozin)
5.1.3 Invokana (Canagliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 US (Market Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.1.2 By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol Myers Squibb, and Others)
5.2.1.2 Canada (Market Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.2.2 By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
5.2.1.3 Rest of North America (Market Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Jardiance, Farxiga, and Invokana)
5.2.1.3.2 By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
6 Competitive Landscape
6.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements
6.2 Market Share Analysis
7 MARKET INDICATORS
7.1 Type-1 Diabetes Population (2012-2024)
7.2 Type-2 Diabetes Population (2012-2024)
8 COMPETITIVE LANDSCAPE
8.1 COMPANY PROFILES
8.1.1 Janssen Pharmaceutical
8.1.2 Eli Lilly
8.1.3 AstraZeneca
8.1.4 Boehringer Ingelheim
8.1.5 Astellas
9 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product (Market Value and Volume, 2012-2024)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Invokana (Canagliflozin)
Geography
North America
US (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, AstraZeneca, Bristol Myers Squibb, and Others)
Canada (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
Rest of North America (Market Value and Volume, 2012-2024)
By Drug (Jardiance, Farxiga, and Invokana)
By Company (NovoNordisk, Sanofi Aventis, Astrazeneca, Bristol Myers Squibb, and Others)
Dipeptide Peptidase 4 (DPP-4) Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 13-06-2019
Market Overview
The global DPP-4 inhibitors market was valued at USD 10.5 billion in 2018 and is expected to record a CAGR of 4% during 2019-2024. The North American DPP-4 drugs segment of the market studied accounted for the highest revenue, in 2018, and Latin America is expected to register the highest CAGR, of approximately 6%, during the forecast period.
Increasing diabetes type-2 and obesity populations will drive the growth of the market in the forecast period.
Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
Scope of the Report
The DPP-4 inhibitors market is segmented by brands and covers the following brands: Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented into five regions: North America, Asia-Pacific, Middle East & Africa, Latin America, and Europe.
Key Market Trends
The Tradjenta Market will Surpass Merck’s Januvia During the Forecast Period
The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018. The Tradjenta market includes its combination Jentadueto and Jentadueto XR, a combination of linagliptin (Tradjenta) and metformin hydrochloride, for use in the treatment of type 2 diabetes. The type-2 diabetes drug, Tradjenta (linagliptin) was not launched in Germany, because of a decision by the county’s reimbursement authority, which concluded that it doesn’t provide any additional benefits, compared to the medicines already on the market.
North America Holds the Highest Market Share
The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share. Increasing diabetes prevalence in established and emerging countries is expected to drive the market. This increase, over the years, is due to the overall effect of individual-level factors, like an increasing median age of the population and health factors, including obesity and inactivity levels among people.
Lowering birth rates, along with increasing life expectancy in countries like Japan, Italy, Germany, and France, which have a high percentage of the geriatric population, are expected to drive the growth of the market.
Competitive Landscape
Merck held the highest market share in the DPP-4 market in 2018 and is expected to maintain its position until 2022. After that, it may witness a decline in market share, due to the expected launch of a generic version of Sitagliptin in 2022.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.1 Januvia (Sitagliptin)
5.1.1.2 Onglyza (Saxagliptin)
5.1.1.3 Tradjenta (Linagliptin)
5.1.1.4 Vipidia/Nesina (Alogliptin)
5.1.1.5 Galvus (Vildagliptin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012-2024)
5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.2 Canada (Value and Volume, 2012-2024)
5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.1.3 Rest of North America (Value and Volume, 2012-2024)
5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012-2024)
5.2.2.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.2 Germany (Value and Volume, 2012-2024)
5.2.2.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.3 Italy (Value and Volume, 2012-2024)
5.2.2.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.4 Spain (Value and Volume, 2012-2024)
5.2.2.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.5 United Kingdom (Value and Volume, 2012-2024)
5.2.2.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.6 Russia (Value and Volume, 2012-2024)
5.2.2.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.2.2.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.2.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012-2024)
5.2.3.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.2 Brazil (Value and Volume, 2012-2024)
5.2.3.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.2.3.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.3.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012-2024)
5.2.4.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.2 South Korea (Value and Volume, 2012-2024)
5.2.4.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.3 China (Value and Volume, 2012-2024)
5.2.4.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.4 India (Value and Volume, 2012-2024)
5.2.4.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.5 Australia (Value and Volume, 2012-2024)
5.2.4.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.6 Vietnam (Value and Volume, 2012-2024)
5.2.4.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.7 Malaysia (Value and Volume, 2012-2024)
5.2.4.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.8 Indonesia (Value and Volume, 2012-2024)
5.2.4.8.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.8.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.9 Philippines (Value and Volume, 2012-2024)
5.2.4.9.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.9.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.10 Thailand (Value and Volume, 2012-2024)
5.2.4.10.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.10.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.2.4.11.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.4.11.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.2.5.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.2 Iran (Value and Volume, 2012-2024)
5.2.5.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.3 Egypt (Value and Volume, 2012-2024)
5.2.5.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.4 Oman (Value and Volume, 2012-2024)
5.2.5.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.5 South Africa (Value and Volume, 2012-2024)
5.2.5.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
5.2.5.6 Rest of Middle East & Africa (Value and Volume, 2012-2024)
5.2.5.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
5.2.5.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Merck And Co.
7.1.2 AstraZeneca
7.1.3 Bristol Myers Squibb
7.1.4 Novartis
7.1.5 Takeda Pharmaceuticals
7.1.6 Eli Lilly
7.1.7 Boehringer Ingelheim
7.2 Company Share Analysis
7.2.1 Merck And Co.
7.2.2 AstraZeneca
7.2.3 Takeda Pharmaceuticals
7.2.4 Novartis
7.2.5 Eli Lilly & Boehringer Ingelheim
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Geography
North America
United States (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Canada (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of North America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Europe
France (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Germany (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Italy (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Spain (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
United Kingdom (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Russia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Europe (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Latin America
Mexico (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Brazil (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Latin America (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Korea (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
China (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
India (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Australia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Vietnam (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Malaysia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Indonesia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Philippines (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Thailand (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Iran (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Egypt (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Oman (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
South Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Rest of Middle East & Africa (Value and Volume, 2012-2024)
By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
Neuromodulation Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 111 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 111 pages
- Published: 12-06-2019
Market Overview
Neurological diseases are frequent in older adults, affecting around 55% of people age 55 and older. They are associated with a high risk for adverse health outcomes, including mortality, disability, institutionalization, and hospitalization. Degenerative diseases, like dementia and Parkinson’s disease, as well as strokes and headaches, are frequently encountered neurological diseases in elderly patients. Neuromodulation is an intracranial, electrical neuromodulation therapy that has FDA approval for the treatment for most of the neurological diseases such as bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most commonly found in the elderly population. The proven efficacy and improving acceptance of this technology are expected to lead to the surge in the market demand during the forecast period.
Scope of the Report
Neuromodulators are a subset of neurotransmitter. Unlike neurotransmitters, the release of neuromodulators occurs in a diffuse manner. This means that an entire neural tissue may be subject to the neuromodulator’s action due to exposure. This, in turn, can tune the neural circuitry of an entire brain region and not just that of an individual neuron.
Key Market Trends
Spinal Cord Stimulation (SCS) Holds the Largest Market Share in the Internal Neuromodulation Type
The process of numbing/reducing chronic pain by passing continuous low voltage electric current to the spinal cord is referred to as spinal cord stimulation (SCS). The SCS devices are FDA approved and are the most widely accepted neurostimulation techniques across the world. These devices are of basic three types namely, rechargeable, conventional, and radiofrequency systems. SCS is used in neurological problems, such as nerve damage, arachnoiditis, failed-back surgery syndrome, neuropathy, complex regional pain syndrome, and neuritis. Along with the associated benefits and effectiveness, SCS also has some pitfalls, such as overstimulation, intermittent stimulation, lead dispositioning, and device malfunctioning. However, the benefits of the SCS outrank the pitfalls, thus boosting the segment’s growth over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall neuromodulation market with the United States accounting as the major contributor to the market. The presence of major market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period. In addition, the rising concern about the prevalence of neurological disorder and other associated disorders is stimulating the need for the adoption of neuromodulation techniques. Asia-Pacific, on the other hand, is expected to grow with the fastest growth rate over the forecast period.
Competitive Landscape
The major market players in the market include Medtronic PLC, Boston Scientific Corporation, St. Jude Medical Inc., Synapse Biomedical Inc., and Nevro Corporation, among others. The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the world.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Neurological Disorders
4.2.2 Increase in the Aging Population
4.2.3 Strong Product Pipeline
4.2.4 Expanded Target Applications and New Indications
4.2.5 Growing Investments
4.3 Market Restraints
4.3.1 Inconsistent Reimbursement Policies
4.3.2 Lack of Trained Professionals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Internal Neuromodulation
5.1.1.1 Spinal Cord Stimulation (SCS)
5.1.1.2 Deep Brain Stimulation (DBS)
5.1.1.3 Vagus Nerve Stimulation (VNS)
5.1.1.4 Sacral Nerve Stimulation (SNS)
5.1.1.5 Gastric Electrical Stimulation (GES)
5.1.2 External Neuromodulation (Non-Invasive)
5.1.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
5.1.2.2 Transcranial Magnetic Stimulation (TMS)
5.1.2.3 Respiratory Electrical Stimulation (RES)
5.2 By Application
5.2.1 Parkinson’s disease
5.2.2 Depression
5.2.3 Chronic Pain
5.2.4 Failed Back Surgery
5.2.5 Ischemia
5.2.6 Urine Incontinence
5.2.7 Fecal Incontinence
5.2.8 Epilepsy
5.2.9 Gastroparesis
5.2.10 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 Boston Scientific Corporation
6.1.3 St. Jude Medical Inc.
6.1.4 Synapse Biomedical Inc.
6.1.5 Nevro Corporation
6.1.6 Neurosigma Inc.
6.1.7 Neuropace Inc.
6.1.8 Neuronetics Inc.
6.1.9 Cyberonics Inc.
6.1.10 BioControl Medical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
Internal Neuromodulation
Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Vagus Nerve Stimulation (VNS)
Sacral Nerve Stimulation (SNS)
Gastric Electrical Stimulation (GES)
External Neuromodulation (Non-Invasive)
Transcutaneous Electrical Nerve Stimulation (TENS)
Transcranial Magnetic Stimulation (TMS)
Respiratory Electrical Stimulation (RES)
By Application
Parkinson’s disease
Depression
Chronic Pain
Failed Back Surgery
Ischemia
Urine Incontinence
Fecal Incontinence
Epilepsy
Gastroparesis
Other Applications
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America